CONMED Corporation
NYSE:CNMDMedical - Devices
+$0.24 today
- Market cap
- $1.43B
- Beta
- 0.92
- P/E (TTM)
- 18.0
- EPS (TTM)
- $1.79
- Dividend yield
- 1.24%
Volume 0.36M
Average 0.45M
CNMD EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
CONMED CorporationNYSE: CNMD
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA growth accelerates
Q1 FY2026 EBITDA of $38.29M rose 32.5% year over year, ahead of the -31.6% change in trailing-twelve-month EBITDA. Sequentially, it fell 31.0% from the prior quarter. Over 3 fiscal years it compounded at +170.6% a year.
Context
- EBITDA amounted to 11.2% of revenue in FY2025, down 9.6 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of $272.04M (+76.0%) for the fiscal year ending Dec 2026, a step up from the -43.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $38.29M-31.0% QoQ
- Last fiscal yearDec 2025
- $154.55M-43.2% YoY
- LTMMar 2026
- $169.63M-31.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +32.5% | +38.4% | +5.8 pp |
| 1 year | -43.2% | +76.0% | +119.2 pp |
| 3-year CAGR | +170.6% | +22.2% | -148.4 pp |
| 5-year CAGR | +16.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 154.55M USD
- Year-over-year change
- -43.2%
- 4-year CAGR
- -3.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 154.55M | -43.2% |
| FY2024 | 2024-12-31 | 272.18M | +41.4% |
| FY2023 | 2023-12-31 | 192.48M | +2368.3% |
| FY2022 | 2022-12-31 | 7.8M | -95.7% |
| FY2021 | 2021-12-31 | 179.33M | — |
EBITDA vs competitors
How CNMD compares with its peers on the latest reported figures
- CNMD's LTM Mar 2026 EBITDA of $169.63M is the 2nd highest of the 11 companies compared; the peer median is -$7.13M.
- Its year-over-year change of -31.6% is the 8th highest of 11, against a peer median of -11.1%.
- EBITDA amounts to 12.4% of revenue for CNMD, versus a peer median of 17.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $462.48M | -25.4% | -7.2% | 16.2% | |
| LTM Mar 2026 | $169.63M | -31.6% | +170.6% | 12.4% | |
| LTM Jun 2026 | $116.08M | +3.1% | +18.3% | 18.4% | |
| LTM Aug 2026 | $105.13M | +112.0% | +9.9% | 11.9% | |
| LTM Mar 2026 | $102.9M | -26.8% | -18.1% | 27.5% | |
| LTM Mar 2026 | -$3.71M | +78.9% | — | 7.7% | |
| LTM Sep 2026 | -$10.54M | +78.0% | — | 4.0% | |
| LTM Sep 2026 | -$94.49M | -265.1% | — | 15.2% | |
| LTM Jan 2026 | -$128M | -87.3% | — | 152.9% | |
| LTM Mar 2026 | -$155.38M | -103.1% | — | 23.0% | |
| LTM Mar 2026 | -$384.61M | +25.4% | — | 581.9% | |
| Peer median (excluding CNMD) | -$7.13M | -11.1% | +1.3% | 17.3% | |
Competitors are the stored peer set for CNMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.01B | 1.05B | 1.24B | 1.31B | 1.37B |
| Cost of Revenue | 442.6M | 474.23M | 568.5M | 573.98M | 649.12M |
| Gross Profit | 568.04M | 571.25M | 676.25M | 733.03M | 725.38M |
| Gross Margin | 56.2% | 54.6% | 54.3% | 56.1% | 52.8% |
| Research & Development | 43.57M | 47.15M | 52.6M | 54.43M | 55.88M |
| Selling, General & Admin | 414.75M | 454.04M | 503.04M | 478.28M | 528.36M |
| Operating Expenses | 458.32M | 501.19M | 555.64M | 532.71M | 584.24M |
| Depreciation & Amortization | 70.74M | 49.76M | 71.87M | 71.86M | 52.34M |
| EBITDA | 179.33M | 7.8M | 192.48M | 272.18M | 154.55M |
| EBITDA Margin | 17.7% | 0.7% | 15.5% | 20.8% | 11.2% |
| Operating Income | 109.72M | 70.05M | 120.6M | 200.33M | 141.13M |
| Operating Margin | 10.9% | 6.7% | 9.7% | 15.3% | 10.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 35.49M | 28.91M | 39.78M | 37.3M | 31.09M |
| Other Income / Expenses | (36.61M) | (140.92M) | (39.78M) | (37.3M) | (70.01M) |
| Income Before Tax | 73.11M | (70.86M) | 80.83M | 163.03M | 71.12M |
| Pre-Tax Margin | 7.2% | -6.8% | 6.5% | 12.5% | 5.2% |
| Income Tax Expense | 10.56M | 9.72M | 16.37M | 30.61M | 24.06M |
| Net Income | 62.54M | (80.58M) | 64.46M | 132.42M | 47.06M |
| Net Margin | 6.2% | -7.7% | 5.2% | 10.1% | 3.4% |
| EPS (Basic) | 2.14 | (2.68) | 2.10 | 4.29 | 1.52 |
| EPS (Diluted) | 1.94 | (2.68) | 2.04 | 4.26 | 1.51 |
| Weighted Avg Shares | 29.16M | 30.04M | 30.67M | 30.85M | 31.04M |
| Weighted Avg Shares (Diluted) | 32.22M | 30.04M | 31.55M | 31.11M | 31.15M |
CONMED Corporation
NYSE:CNMD
Intrinsic Alpha fair value
Locked
Current Price
$48.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.